Difference between revisions of "Interferon alfa-2a (Roferon-A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Renal cancer" to "[[Renal cell carcinoma")
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
Line 37: Line 37:
 
[[Category:Squamous cell carcinoma (SCC) medications]]
 
[[Category:Squamous cell carcinoma (SCC) medications]]
  
−
[[Category:Drugs FDA approved in 1986]]
+
[[Category:FDA approved in 1986]]

Revision as of 19:19, 30 July 2018

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 6/4/1986: Initial FDA approval

Also known as

  • Brand name: Roferon-A

References

  1. ↑ 1.0 1.1 Interferon alfa-2a (Roferon-A) package insert
  2. ↑ Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)
  3. ↑ Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)
Retrieved from "https://hemonc.org/w/index.php?title=Interferon_alfa-2a_(Roferon-A)&oldid=29351"